160590-36-3

Basic information

• Product Name: 2-METHOXY-3-NITRO-4-PICOLINE
• Synonyms: 2-METHOXY-3-NITRO-4-PICOLINE;2-methoxy-3-nitro-4-methylpyridine;Pyridine,2-Methoxy-4-Methyl-3-nitro-
• CAS NO: 160590-36-3
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 168.15
• Product Categories: Pyridine
• Mol File: 160590-36-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 38-40℃
• Boiling Point: 270℃
• Flash Point: 117℃
• Appearance: /
• Density: 1.247
• Vapor Pressure: 0.011mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.02±0.18(Predicted)
• CAS DataBase Reference: 2-METHOXY-3-NITRO-4-PICOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-3-NITRO-4-PICOLINE(160590-36-3)
• EPA Substance Registry System: 2-METHOXY-3-NITRO-4-PICOLINE(160590-36-3)

Safety Data

• Hazardous Substances Data: 160590-36-3(Hazardous Substances Data)

Usage

General Description

2-Methoxy-3-nitro-4-picoline is a chemical compound with the molecular formula C7H7NO3. It is a member of the picoline family, which is a group of heterocyclic aromatic compounds. 2-Methoxy-3-nitro-4-picoline is used in the pharmaceutical and agrochemical industries as a building block for the synthesis of various drugs and chemicals. It is also used as a reagent in organic synthesis and as a research chemical. 2-METHOXY-3-NITRO-4-PICOLINE is known to be toxic and harmful if swallowed, inhaled, or in contact with skin, and it should be handled with proper safety precautions.

InChI:InChI=1/C7H8N2O3/c1-5-3-4-8-7(12-2)6(5)9(10)11/h3-4H,1-2H3

Upstream product

• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 

Downstream Products

• 1445993-89-4 6-methyl-1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 2412985-61-4 4-bromo-1,6-dimethylpyrrolo[2,3-c]pyridin-7-one 

Relevant articles and documents

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains

The biological role played by non-BET bromodomains remains poorly understood, and it is therefore imperative to identify potent and highly selective inhibitors to effectively explore the biology of individual bromodomain proteins. A ligand-efficient nonselective bromodomain inhibitor was identified from a 6-methyl pyrrolopyridone fragment. Small hydrophobic substituents replacing the N-methyl group were designed directing toward the conserved bromodomain water pocket, and two distinct binding conformations were then observed. The substituents either directly displaced and rearranged the conserved solvent network, as in BRD4(1) and TAF1(2), or induced a narrow hydrophobic channel adjacent to the lipophilic shelf, as in BRD9 and CECR2. The preference of distinct substituents for individual bromodomains provided selectivity handles useful for future lead optimization efforts for selective BRD9, CECR2, and TAF1(2) inhibitors.

SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN

The present invention relates to compounds of formula (I) and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.